US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
ATE526950T1
(de)
|
1999-10-29 |
2011-10-15 |
Euro Celtique Sa |
Hydrocodon-formulierungen mit gesteuerter freisetzung
|
JP5767429B2
(ja)
*
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
EP2263658A1
(en)
|
2000-10-30 |
2010-12-22 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
NZ535456A
(en)
*
|
2002-02-21 |
2006-08-31 |
Biovail Lab Int Srl |
Modified release formulations of at least one form of tramadol for oral administration
|
US8323692B2
(en)
|
2002-02-21 |
2012-12-04 |
Valeant International Bermuda |
Controlled release dosage forms
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
KR100897890B1
(ko)
|
2002-06-17 |
2009-05-18 |
인벤티아 헬스케어 피브이티. 엘티디. |
티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
|
US7704527B2
(en)
*
|
2002-10-25 |
2010-04-27 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
DE10307728B4
(de)
*
|
2003-02-24 |
2005-09-22 |
Clariant Gmbh |
Korrosions-und Gashydratinhibitoren mit verbesserter Wasserlöslichkeit und erhöhter biologischer Abbaubarkeit und derartige Verbindungen
|
ES2278314T3
(es)
*
|
2003-04-17 |
2007-08-01 |
Jallal Messadek |
Formulaciones orales para la liberacion controlada de la betaina.
|
CN1784221B
(zh)
|
2003-04-29 |
2010-07-07 |
奥雷西根治疗公司 |
影响体重减轻的组合物
|
US20090214644A1
(en)
*
|
2003-07-31 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
US20050025825A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
WO2005065639A2
(en)
*
|
2003-11-21 |
2005-07-21 |
Torrent Pharmaceuticals Limited |
Novel pharmaceutical compositions
|
CZ300438B6
(cs)
*
|
2003-11-25 |
2009-05-20 |
Pliva Hrvatska D.O.O. |
Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
|
US20050163842A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Rosiglitazone and metformin formulations
|
US8022106B2
(en)
*
|
2004-03-04 |
2011-09-20 |
Ferring B.V. |
Tranexamic acid formulations
|
US7947739B2
(en)
|
2004-03-04 |
2011-05-24 |
Ferring B.V. |
Tranexamic acid formulations
|
US20090215898A1
(en)
*
|
2004-03-04 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US20050245614A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US20050244495A1
(en)
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US20060185357A1
(en)
*
|
2004-05-07 |
2006-08-24 |
Kovacevich Ian D |
Independently drawing and tensioning lines with bi-directional rotary device having two spools
|
US20080181946A1
(en)
*
|
2004-05-14 |
2008-07-31 |
Braj Bhushan Lohray |
Controlled Release Delivery System For Metformin
|
DE602005025755D1
(de)
|
2004-06-04 |
2011-02-17 |
Teva Pharma |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
BE1016128A6
(fr)
*
|
2004-07-22 |
2006-03-07 |
Messadek Jallal |
Combinaisons therapeutiques
|
US7700608B2
(en)
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
AR050615A1
(es)
*
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
CZ296459B6
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
WO2006031024A1
(en)
|
2004-09-15 |
2006-03-23 |
Gl Pharmtech Corp. |
A sustained-release tablet containing doxazosin mesylate
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0502479D0
(en)
*
|
2005-02-07 |
2005-03-16 |
Sb Pharmco Inc |
Novel compositions
|
WO2006086856A1
(en)
*
|
2005-02-15 |
2006-08-24 |
Messadek, Jallal |
Combination therapeutic compositions and method of use
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
MX2007012374A
(es)
|
2005-04-06 |
2008-02-22 |
Adamas Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
|
US7348027B2
(en)
*
|
2005-04-08 |
2008-03-25 |
Bayer Healthcare Llc |
Taste masked veterinary formulation
|
US20060229261A1
(en)
*
|
2005-04-12 |
2006-10-12 |
John Devane |
Acarbose methods and formulations for treating chronic constipation
|
US20100087546A1
(en)
*
|
2005-04-20 |
2010-04-08 |
Biogenic Innovations, Llc |
Use of dimethyl sulfone (msm) to reduce homocysteine levels
|
KR20080028361A
(ko)
*
|
2005-05-03 |
2008-03-31 |
뮤추얼 파마슈티컬 컴퍼니 아이엔씨. |
퀴닌-함유 제어-방출형 제제
|
US8088773B2
(en)
*
|
2005-05-12 |
2012-01-03 |
The Texas A&M University System |
Therapeutic compositions and methods
|
US20070225322A1
(en)
*
|
2005-05-25 |
2007-09-27 |
Transoral Pharmaceuticals, Inc. |
Compositions and methods for treating middle-of-the night insomnia
|
US20060276501A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Transoral Pharmaceuticals, Inc. |
Solid compositions for treating middle-of-the-night insomnia
|
US20070287740A1
(en)
*
|
2005-05-25 |
2007-12-13 |
Transcept Pharmaceuticals, Inc. |
Compositions and methods of treating middle-of-the night insomnia
|
US7544373B2
(en)
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7919483B2
(en)
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
US7776870B2
(en)
|
2005-08-22 |
2010-08-17 |
Melior Pharmaceuticals I, Inc. |
Methods for modulating Lyn kinase activity and treating related disorders
|
RU2385712C2
(ru)
*
|
2005-08-24 |
2010-04-10 |
Рубикон Рисёч Пвт Лтд. |
Рецептура с контролируемым высвобождением
|
US8435224B2
(en)
|
2005-09-12 |
2013-05-07 |
Abela Pharmaceuticals, Inc. |
Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
|
EP1966229B1
(en)
|
2005-09-12 |
2015-10-21 |
Abela Pharmaceuticals, Inc. |
Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
|
US8480797B2
(en)
*
|
2005-09-12 |
2013-07-09 |
Abela Pharmaceuticals, Inc. |
Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
|
EP1937286B1
(en)
|
2005-09-12 |
2016-03-09 |
Abela Pharmaceuticals, Inc. |
Compositions comprising dimethyl sulfoxide (dmso)
|
DE102005054610B4
(de)
*
|
2005-11-08 |
2010-06-10 |
Awd.Pharma Gmbh & Co. Kg |
Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
|
US20070203079A1
(en)
*
|
2005-11-21 |
2007-08-30 |
Caldwell Guy A |
Methods of using small molecule compounds for neuroprotection
|
MX337422B
(es)
|
2005-11-22 |
2016-03-04 |
Orexigen Therapeutics Inc |
Composiciones y metodos para incrementar la sencibilidad a la insulina.
|
EP1954241B1
(en)
*
|
2005-11-28 |
2012-02-29 |
Orexigen Therapeutics, Inc. |
Sustained-release formulation of zonisamide
|
FR2896157B1
(fr)
*
|
2006-01-13 |
2008-09-12 |
Merck Sante Soc Par Actions Si |
Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
|
US7427414B2
(en)
*
|
2006-01-18 |
2008-09-23 |
Astron Research Limited |
Modified release oral dosage form using co-polymer of polyvinyl acetate
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
US7811549B2
(en)
|
2006-07-05 |
2010-10-12 |
Adenobio N.V. |
Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
KR20090037930A
(ko)
*
|
2006-07-11 |
2009-04-16 |
뮤추얼 파마슈티컬 컴퍼니 아이엔씨. |
조절 방출 제형
|
US8765178B2
(en)
*
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
CN101500983B
(zh)
*
|
2006-07-26 |
2015-09-16 |
于崇曦 |
具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
|
CN105439877B
(zh)
*
|
2006-07-26 |
2019-07-23 |
于崇曦 |
带正电荷的水溶性二氟尼柳及相关化合物的前药
|
DK2049123T4
(en)
|
2006-08-03 |
2016-11-28 |
Horizon Pharma Ag |
LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
|
WO2008021666A2
(en)
*
|
2006-08-18 |
2008-02-21 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
CA2659952A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Wyeth |
8-hydroxyquinoline compounds and methods thereof
|
US20080051375A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
US20080075785A1
(en)
*
|
2006-09-22 |
2008-03-27 |
San-Laung Chow |
Controlled release hydrogel formulation
|
US20110165236A1
(en)
*
|
2006-09-22 |
2011-07-07 |
Biokey, Inc. |
Controlled release hydrogel formulation
|
TWI609702B
(zh)
|
2006-11-09 |
2018-01-01 |
歐瑞根治療有限公司 |
層狀醫藥調配物
|
KR20140088619A
(ko)
|
2006-11-09 |
2014-07-10 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
ES2312308T3
(es)
|
2006-11-17 |
2013-03-26 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de liberación sostenida de topiramato
|
KR100822180B1
(ko)
*
|
2006-11-22 |
2008-04-16 |
광동제약 주식회사 |
마진돌 함유 정제의 안정화 방법
|
WO2008066845A2
(en)
*
|
2006-11-28 |
2008-06-05 |
Ampla Pharmaceuticals Inc. |
Treatment of metabolic syndrome with norfluoxetine
|
US20080132535A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Transcept Pharmaceuticals, Inc. |
Stabilized Zolpidem Pharmaceutical Compositions
|
AU2007329373B2
(en)
*
|
2006-12-04 |
2013-06-20 |
Supernus Pharmaceuticals, Inc. |
Enhanced immediate release formulations of topiramate
|
ATE543501T1
(de)
*
|
2006-12-20 |
2012-02-15 |
Cardoz Ab |
Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen
|
AU2007344274A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Cardoz Ab |
New combination for use in the treatment of inflammatory disorders
|
US20100143270A1
(en)
*
|
2007-02-21 |
2010-06-10 |
University Of Louisville Research Foubdation |
Therapeutic cotinine compositions
|
EP1967182A1
(en)
*
|
2007-03-07 |
2008-09-10 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising a salt of rosigliatazone
|
EP2123275A1
(en)
*
|
2007-03-15 |
2009-11-25 |
Toyo Boseki Kabushiki Kaisha |
Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
|
WO2008114280A1
(en)
*
|
2007-03-21 |
2008-09-25 |
Lupin Limited |
Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
|
KR100782310B1
(ko)
|
2007-03-22 |
2007-12-06 |
현대약품 주식회사 |
갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
|
WO2008121107A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20160331729A9
(en)
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
EP3053440B1
(en)
*
|
2007-04-11 |
2020-08-12 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
WO2008150845A1
(en)
*
|
2007-05-31 |
2008-12-11 |
Vanderbilt University |
Screening for wnt pathway modulators and pyrvinium for the treatment of cance
|
JP2010529101A
(ja)
*
|
2007-06-04 |
2010-08-26 |
テックフィールズ インコーポレイテッド |
非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
|
US20090004231A1
(en)
|
2007-06-30 |
2009-01-01 |
Popp Shane M |
Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
|
US8404275B2
(en)
*
|
2007-07-01 |
2013-03-26 |
Vitalis Llc |
Combination tablet with chewable outer layer
|
WO2009007680A2
(en)
|
2007-07-11 |
2009-01-15 |
Cardoz Ab |
Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
|
WO2009009132A1
(en)
*
|
2007-07-12 |
2009-01-15 |
Cougar Biotechnology, Inc. |
Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
|
US8067632B2
(en)
*
|
2007-07-26 |
2011-11-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Process to produce prostratin and structural or functional analogs thereof
|
US20090035370A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Drugtech Corporation |
Dosage form and method of use
|
WO2009019599A2
(en)
|
2007-08-08 |
2009-02-12 |
Themis Laboratories Private Limited |
Extended release compositions comprising tolterodine
|
US8802156B2
(en)
|
2007-11-14 |
2014-08-12 |
Laboratorios Farmacéuticos Rovi, S.A. |
Pharmaceutical forms for the release of active compounds
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
US20090185973A1
(en)
*
|
2008-01-22 |
2009-07-23 |
Adenobio N.V. |
Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
|
CA2713581A1
(en)
*
|
2008-02-28 |
2009-09-03 |
Novartis Ag |
Valsartan solid oral dosage forms and methods of making such formulations
|
WO2009114520A2
(en)
*
|
2008-03-10 |
2009-09-17 |
Pharmain Corporation |
Compositions for treatment with metallopeptidases, methods of making and using the same
|
CN101550162B
(zh)
*
|
2008-04-03 |
2015-11-25 |
北京华昊中天生物技术有限公司 |
福司曲星衍生物及其药用用途
|
EP2303251B1
(en)
*
|
2008-04-07 |
2012-05-16 |
Cardoz AB |
New combination for use in the treatment of inflammatory disorders
|
PT2276473T
(pt)
|
2008-04-18 |
2016-12-15 |
Intec Pharma Ltd |
Entrega de fármacos gastro-retentiva para carbidopa/levodopa
|
KR101591482B1
(ko)
|
2008-05-28 |
2016-02-03 |
레베라겐 바이오파마 인코포레이티드 |
질환의 치료를 위한 NF-κB 의 비호르몬성 스테로이드 조절제
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
AU2009256394A1
(en)
*
|
2008-06-02 |
2009-12-10 |
Dr. Reddy's Laboratories Ltd. |
Modified release niacin formulations
|
US20100178341A1
(en)
*
|
2008-06-11 |
2010-07-15 |
Ranbaxy Laboratories Limited |
BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
CA2732513C
(en)
|
2008-08-01 |
2017-04-25 |
Arca Biopharma, Inc. |
Methods and compositions involving (s)-bucindolol
|
WO2010017310A1
(en)
|
2008-08-06 |
2010-02-11 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
WO2010025135A2
(en)
*
|
2008-08-28 |
2010-03-04 |
Osteogenex Inc. |
Trimeprazine and ethopropazine derivatives for promoting bone growth
|
US20110144055A1
(en)
*
|
2008-09-04 |
2011-06-16 |
Rozmanith Anthony I |
Health Care
|
US20100068254A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Mahalaxmi Gita Bangera |
Modifying a medicament availability state of a final dosage form
|
US20100068233A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Modifiable dosage form
|
US20100068235A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete LLC, a limited liability corporation of Deleware |
Individualizable dosage form
|
US20100069821A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-sites final dosage form
|
US20100069887A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Multiple chamber ex vivo adjustable-release final dosage form
|
US20100068278A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liablity Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-associations
|
US20100068275A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Personalizable dosage form
|
US8198268B2
(en)
*
|
2008-10-31 |
2012-06-12 |
Janssen Biotech, Inc. |
Tianeptine sulfate salt forms and methods of making and using the same
|
BRPI0921494A2
(pt)
|
2008-11-03 |
2018-10-30 |
Prad Reasearch And Development Ltd |
método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
|
US8771735B2
(en)
*
|
2008-11-04 |
2014-07-08 |
Jazz Pharmaceuticals, Inc. |
Immediate release dosage forms of sodium oxybate
|
US8778398B2
(en)
*
|
2008-11-04 |
2014-07-15 |
Jazz Pharmaceuticals, Inc. |
Immediate release formulations and dosage forms of gamma-hydroxybutyrate
|
US9693981B2
(en)
*
|
2008-12-04 |
2017-07-04 |
Intec Pharma Ltd. |
Zaleplon gastroretentive drug delivery system
|
MX362949B
(es)
|
2008-12-04 |
2019-02-27 |
Yu Chongxi |
Composiciones de alta penetracion y sus aplicaciones.
|
US20100183717A1
(en)
*
|
2009-01-16 |
2010-07-22 |
Kristin Arnold |
Controlled-release formulations
|
EP2391369A1
(en)
*
|
2009-01-26 |
2011-12-07 |
Nitec Pharma AG |
Delayed-release glucocorticoid treatment of asthma
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
CA2752233C
(en)
*
|
2009-02-13 |
2017-01-03 |
Romark Laboratories L.C. |
Controlled release pharmaceutical formulations of nitazoxanide
|
US20100280117A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Xanodyne Pharmaceuticals, Inc. |
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
|
WO2010134938A1
(en)
*
|
2009-05-18 |
2010-11-25 |
Dr. Reddy's Laboratories Ltd. |
Modified release niacin pharmaceutical formulations
|
MX364974B
(es)
|
2009-05-19 |
2019-05-16 |
Neuroderm Ltd |
Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
|
CN106177963A
(zh)
*
|
2009-06-05 |
2016-12-07 |
陶制药有限责任公司 |
用于治疗癌症或癌前病症的交错方法
|
MX353712B
(es)
|
2009-10-30 |
2018-01-24 |
Abela Pharmaceuticals Inc |
Formulaciones de sulfoxido de dimetilo (dmso) y metilsulfonilmetano (msm) para tratar osteoartritis.
|
FI2504353T4
(fi)
|
2009-11-23 |
2023-11-30 |
Cubist Pharmaceuticals Llc |
Lipopeptidikoostumukset ja vastaavat menetelmät
|
CA2782556C
(en)
|
2009-12-02 |
2018-03-27 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
KR101479824B1
(ko)
*
|
2009-12-18 |
2015-01-06 |
미쓰비시 타나베 파마 코퍼레이션 |
용출 안정성 제제
|
NL1037569C2
(en)
*
|
2009-12-18 |
2011-06-21 |
Eurovet Animal Health B V |
Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
|
US20110150986A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Kristin Arnold |
Quinine formulations, method of making, and metho of use thereof
|
KR101841442B1
(ko)
|
2010-01-11 |
2018-03-23 |
오렉시젠 세러퓨틱스 인크. |
주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
|
USD661900S1
(en)
|
2010-02-22 |
2012-06-19 |
Bajer Design & Marketing, Inc. |
Collapsible structure
|
JP6017964B2
(ja)
|
2010-03-01 |
2016-11-02 |
ティーエーユー・セラピューティクス・エルエルシー |
癌診断および撮像
|
MX339408B
(es)
*
|
2010-03-09 |
2016-05-24 |
Alkermes Pharma Ireland Ltd |
Composiciones farmaceuticas entericas resistentes al alcohol.
|
US20120076865A1
(en)
|
2010-03-24 |
2012-03-29 |
Jazz Pharmaceuticals, Inc. |
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
|
EP2556083A4
(en)
|
2010-04-05 |
2013-12-04 |
Validus Biopharma Inc |
NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
|
JP2013526523A
(ja)
|
2010-05-11 |
2013-06-24 |
シマ ラブス インク. |
メトプロロールを含むアルコール耐性持続放出性経口剤形
|
WO2011150300A1
(en)
|
2010-05-28 |
2011-12-01 |
Melior Pharmaceuticals I, Inc. |
Prevention of pancreatic beta cell degeneration
|
US8846723B2
(en)
|
2010-07-29 |
2014-09-30 |
Eastman Chemical Company |
Esters of O-substituted hydroxy carboxylic acids and preparations thereof
|
US20120052011A1
(en)
*
|
2010-08-24 |
2012-03-01 |
Canon Kabushiki Kaisha |
Composition and a method for producing contrast agent using the composition
|
US8916194B2
(en)
*
|
2010-08-30 |
2014-12-23 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
ES2776734T3
(es)
|
2010-11-15 |
2020-07-31 |
Neuroderm Ltd |
Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello
|
US8597683B2
(en)
|
2010-11-30 |
2013-12-03 |
Watson Pharmaceuticals, Inc. |
Modified release tranexamic acid formulation
|
CA2827336C
(en)
|
2011-02-23 |
2016-01-26 |
Coeruleus Ltd. |
Flumazenil complexes, compositions comprising same and uses thereof
|
CA2836253C
(en)
|
2011-05-16 |
2021-02-16 |
Romark Laboratories, L.C. |
Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
|
WO2012171015A2
(en)
*
|
2011-06-10 |
2012-12-13 |
Translational Genomics Research Institute |
Therapeutic combination for cancer treatment
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
EP3078374B1
(en)
*
|
2011-10-17 |
2019-06-19 |
Vanderbilt University |
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
|
CA2853804C
(en)
|
2011-10-28 |
2021-06-01 |
Vitalis Llc |
Anti-flush compositions
|
US9717678B2
(en)
*
|
2011-11-06 |
2017-08-01 |
Murty Pharmaceuticals, Inc. |
Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
|
EP2790704B1
(en)
*
|
2011-12-12 |
2019-04-03 |
Melior Pharmaceuticals I, Inc. |
Treatment of type i diabetes
|
US20130183263A1
(en)
|
2012-01-17 |
2013-07-18 |
Steven Hoffman |
Pharmaceutical compositions and methods
|
US10646552B2
(en)
|
2012-01-17 |
2020-05-12 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
US10272068B2
(en)
|
2012-01-17 |
2019-04-30 |
Tyme, Inc. |
Pharmaceutical compositions and methods
|
WO2013142314A1
(en)
*
|
2012-03-19 |
2013-09-26 |
Althera Life Sciences, Llc |
Oral tablet formulation consisting of immediate release rosuv astatin and extended release metformin
|
JP6378170B2
(ja)
|
2012-04-12 |
2018-08-22 |
イェール ユニバーシティーYale University |
異なる医薬品の制御送達のためのビヒクル
|
JP6175492B2
(ja)
*
|
2012-04-30 |
2017-08-02 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
呼気中アセトン検出用センサ組成物
|
CN104349768B
(zh)
|
2012-06-05 |
2017-11-07 |
纽罗德姆有限公司 |
包含阿朴吗啡和有机酸的组合物及其用途
|
CA2875056C
(en)
|
2012-06-06 |
2024-03-26 |
Orexigen Therapeutics, Inc. |
Methods of treating overweight and obesity
|
RU2521572C1
(ru)
*
|
2012-12-21 |
2014-06-27 |
Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) |
Сокристаллическая форма фенбуфена
|
WO2014122671A2
(en)
*
|
2013-02-08 |
2014-08-14 |
Hetero Research Foundation |
Solid oral compositions of saxagliptin
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
WO2014203140A1
(en)
|
2013-06-22 |
2014-12-24 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
|
US10195153B2
(en)
|
2013-08-12 |
2019-02-05 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
KR102460800B1
(ko)
|
2013-11-01 |
2022-10-31 |
예일 유니버시티 |
면역요법용 모듈러 입자
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
WO2015095971A1
(en)
|
2013-12-23 |
2015-07-02 |
Socpra Sciences Et Génie S.E.C. |
Atp synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
|
MX2016011837A
(es)
|
2014-03-13 |
2017-04-27 |
Neuroderm Ltd |
Composiciones de inhibidores de la dopa decarboxilasa.
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
CN111956653B
(zh)
*
|
2014-05-08 |
2023-06-30 |
上海市生物医药技术研究院 |
双炔失碳酯组合物和疾病治疗方法
|
HUE043399T2
(hu)
*
|
2014-06-26 |
2019-08-28 |
Hennig Arzneimittel Gmbh&Co Kg |
Gyógyszer, különbözõ okokból eredõ szédülés kezelésére
|
JP6371463B2
(ja)
|
2014-07-17 |
2018-08-08 |
ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド |
即時放出性乱用抑止性液体充填剤形
|
EP3209282A4
(en)
|
2014-10-20 |
2018-05-23 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
CN104523636B
(zh)
*
|
2014-12-25 |
2017-07-18 |
昆明振华制药厂有限公司 |
一种呋喃唑酮缓释片及其制备方法
|
US9750785B2
(en)
|
2015-01-30 |
2017-09-05 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9687526B2
(en)
|
2015-01-30 |
2017-06-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9744209B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9937223B2
(en)
|
2015-01-30 |
2018-04-10 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9925233B2
(en)
|
2015-01-30 |
2018-03-27 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US9744239B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US10398662B1
(en)
|
2015-02-18 |
2019-09-03 |
Jazz Pharma Ireland Limited |
GHB formulation and method for its manufacture
|
US10722527B2
(en)
|
2015-04-10 |
2020-07-28 |
Capsugel Belgium Nv |
Abiraterone acetate lipid formulations
|
US10799514B2
(en)
|
2015-06-29 |
2020-10-13 |
Reveragen Biopharma, Inc. |
Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
|
KR101663543B1
(ko)
*
|
2015-07-29 |
2016-10-07 |
고려대학교 산학협력단 |
부스피론 유도체 및 이를 함유하는 약학 조성물
|
US11648212B2
(en)
*
|
2016-02-03 |
2023-05-16 |
Intelgenx Corp. |
Loxapine film oral dosage form
|
CN109715156A
(zh)
|
2016-07-14 |
2019-05-03 |
尔察祯有限公司 |
用于治疗细菌感染的头孢布烯和克拉维酸的组合
|
UY37341A
(es)
|
2016-07-22 |
2017-11-30 |
Flamel Ireland Ltd |
Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
|
US11986451B1
(en)
|
2016-07-22 |
2024-05-21 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11602512B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11504347B1
(en)
|
2016-07-22 |
2022-11-22 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11602513B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US10695450B2
(en)
|
2016-07-26 |
2020-06-30 |
Laboratoires Cyclopharma |
Synthesis of a radioactive agent composition
|
JP2019522032A
(ja)
|
2016-07-29 |
2019-08-08 |
ヤンセン ファーマシューティカ エヌ.ベー. |
前立腺癌の治療方法
|
EP3518910A4
(en)
|
2016-09-30 |
2020-11-04 |
Xenamed Corporation |
MIDODRIN COMPOSITIONS AND METHOD OF USE THEREOF
|
US10711032B2
(en)
*
|
2016-11-08 |
2020-07-14 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
EP3592350A4
(en)
|
2017-03-10 |
2020-12-23 |
Embera NeuroTherapeutics, Inc. |
PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
|
US20180263936A1
(en)
|
2017-03-17 |
2018-09-20 |
Jazz Pharmaceuticals Ireland Limited |
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
|
BR112019021140A2
(pt)
|
2017-04-10 |
2020-05-19 |
Univ Louisiana State |
composição, método para reduzir os níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento, método de indução do bege de adipócitos ou prevenção da degeneração das células beta do pâncreas, e, ativador de lyn cinase e agonista de trpm8 para uso na redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento.
|
US11478467B2
(en)
*
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
US20180318319A1
(en)
|
2017-05-04 |
2018-11-08 |
Ocular Science, Inc. |
Compositions and Methods for Treating Eyes and Methods of Preparation
|
WO2018213713A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Embera Neurotherapeutics, Inc. |
Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
|
WO2019014201A1
(en)
*
|
2017-07-10 |
2019-01-17 |
Apicore Us Llc |
MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE
|
CN111372578A
(zh)
|
2017-08-24 |
2020-07-03 |
阿达玛斯药物有限责任公司 |
金刚烷胺组合物、其制备和使用方法
|
MX2020004107A
(es)
|
2017-10-25 |
2020-07-24 |
Chiesi Farm Spa |
Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
|
KR20200110648A
(ko)
|
2017-12-05 |
2020-09-24 |
선오비온 파마슈티컬스 인코포레이티드 |
비라세믹 혼합물 및 이의 용도
|
KR20200110317A
(ko)
|
2017-12-05 |
2020-09-23 |
선오비온 파마슈티컬스 인코포레이티드 |
결정형 및 이의 제조 방법
|
WO2019126770A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Xenamed Corp. |
Extended release midodrine hydrochloride compositions and methods of use
|
EP3546589B1
(de)
*
|
2018-03-29 |
2022-08-10 |
Evonik Operations GmbH |
Verfahren zur herstellung von sphingolipiden
|
US10799138B2
(en)
|
2018-04-05 |
2020-10-13 |
University Of Maryland, Baltimore |
Method of administering sotalol IV/switch
|
US11643438B2
(en)
|
2018-07-20 |
2023-05-09 |
The Board Of Regents Of The University Of Oklahoma |
Antimicrobial peptides and methods of use
|
US10512620B1
(en)
|
2018-08-14 |
2019-12-24 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
US11610660B1
(en)
|
2021-08-20 |
2023-03-21 |
AltaThera Pharmaceuticals LLC |
Antiarrhythmic drug dosing methods, medical devices, and systems
|
US11344518B2
(en)
|
2018-08-14 |
2022-05-31 |
AltaThera Pharmaceuticals LLC |
Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
|
US11696902B2
(en)
|
2018-08-14 |
2023-07-11 |
AltaThera Pharmaceuticals, LLC |
Method of initiating and escalating sotalol hydrochloride dosing
|
KR20210042412A
(ko)
|
2018-09-06 |
2021-04-19 |
주식회사 이노파마스크린 |
천식 또는 파킨슨병 치료를 위한 방법 및 조성물
|
US20200093884A1
(en)
|
2018-09-20 |
2020-03-26 |
Mark C. Manning |
Stable intranasal formulations of carbetocin
|
CA3112190A1
(en)
|
2018-09-20 |
2020-03-26 |
Levo Therapeutics, Inc. |
Carbetocin drug product and process for preparing same
|
AU2019383389A1
(en)
|
2018-11-19 |
2021-05-06 |
Jazz Pharmaceuticals Ireland Limited |
Alcohol-resistant drug formulations
|
KR20200077911A
(ko)
*
|
2018-12-21 |
2020-07-01 |
(주)유케이케미팜 |
잘토프로펜 함유 서방성 의약 조성물
|
US10869860B2
(en)
|
2018-12-28 |
2020-12-22 |
Vividion Therapeutics, Inc. |
Cereblon modulators and uses thereof
|
CA3127871A1
(en)
|
2019-03-01 |
2020-09-10 |
Flamel Ireland Limited |
Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
|
US11382922B2
(en)
|
2019-03-07 |
2022-07-12 |
Reveragen Biopharma, Inc. |
Aqueous oral pharmaceutical suspension compositions
|
EP3965733A4
(en)
|
2019-05-07 |
2023-01-11 |
Clexio Biosciences Ltd. |
ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
US11071724B2
(en)
|
2019-05-17 |
2021-07-27 |
Ocular Science, Inc. |
Compositions and methods for treating presbyopia
|
AU2020286441A1
(en)
|
2019-06-04 |
2022-01-06 |
Sunovion Pharmaceuticals Inc. |
Modified release formulations and uses thereof
|
CN111000844B
(zh)
*
|
2019-12-19 |
2022-06-28 |
浙江立恩生物科技有限公司 |
一种治疗流感病毒感染的药物
|
CN110903247B
(zh)
*
|
2019-12-23 |
2022-04-05 |
常州齐晖药业有限公司 |
一种大幅降低奥芬达唑杂质b的制备方法
|
US11638722B2
(en)
|
2020-03-25 |
2023-05-02 |
Therapeutica Borealis Oy C/O Avance Attorneys Ltd. |
Medicine for Covid-19 and treatment
|
US11278602B2
(en)
|
2020-03-25 |
2022-03-22 |
Therapeutica Borealis Oy |
Medicine for Covid-19 and treatment
|
US11007187B1
(en)
*
|
2020-03-25 |
2021-05-18 |
Therapeutica Borealis Oy |
Medicine for Covid-19 and treatment
|
CN112089823B
(zh)
*
|
2020-09-25 |
2024-02-06 |
珠海中科先进技术研究院有限公司 |
一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂
|
WO2022091065A1
(ko)
*
|
2020-11-02 |
2022-05-05 |
(주)아이엠디팜 |
신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
CN113069421A
(zh)
*
|
2021-03-29 |
2021-07-06 |
海南锦瑞制药有限公司 |
注射用兰索拉唑
|
US11583510B1
(en)
|
2022-02-07 |
2023-02-21 |
Flamel Ireland Limited |
Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
|
US11779557B1
(en)
|
2022-02-07 |
2023-10-10 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US12016851B2
(en)
|
2022-04-11 |
2024-06-25 |
Chiesi Farmaceutici S.P.A. |
Modified release pharmaceutical formulations comprising deferiprone
|
US12016850B2
(en)
|
2022-04-11 |
2024-06-25 |
Chiesi Farmaceutici S.P.A. |
Modified release pharmaceutical formulations comprising deferiprone
|
CN116407557A
(zh)
*
|
2023-05-29 |
2023-07-11 |
四川大学华西医院 |
一种防治出血性脑卒中的药物组合物及其应用
|
CN117607311B
(zh)
*
|
2024-01-19 |
2024-03-29 |
地奥集团成都药业股份有限公司 |
一种盐酸贝那普利对映异构体的检测方法
|